title: Phase separation behavior of fusidic acid and rifampicin in PLGA microspheres.
abstract: The purpose of this study was to characterize the phase separation behavior of fusidic acid (FA) and rifampicin (RIF) in poly(d,l-lactic acid-co-glycolic acid) (PLGA) using a model microsphere formulation. To accomplish this, microspheres containing 20% FA with 0%, 5%, 10%, 20%, and 30% RIF and 20% RIF with 30%, 20% 10%, 5%, and 0% FA were prepared by solvent evaporation. Drug-polymer and drug-drug compatibility and miscibility were characterized using laser confocal microscopy, Raman spectroscopy, XRPD, DSC, and real-time video recordings of single-microsphere formation. The encapsulation of FA and RIF alone, or in combination, results in a liquid-liquid phase separation of solvent-and-drug-rich microdomains that are excluded from the polymer bulk during microsphere hardening, resulting in amorphous spherical drug-rich domains within the polymer bulk and on the microsphere surface. FA and RIF phase separate from PLGA at relative droplet volumes of 0.311 ± 0.014 and 0.194 ± 0.000, respectively, predictive of the incompatibility of each drug and PLGA. When coloaded, FA and RIF phase separate in a single event at the relative droplet volume 0.251 ± 0.002, intermediate between each of the monoloaded formulations and dependent on the relative contribution of FA or RIF. The release of FA and RIF from phase-separated microspheres was characterized exclusively by a burst release and was dependent on the phase exclusion of surface drug-rich domains. Phase separation results in coalescence of drug-rich microdroplets and polymer phase exclusion, and it is dependent on the compatibility between FA and RIF and PLGA. FA and RIF are mutually miscible in all proportions as an amorphous glass, and they phase separate from the polymer as such. These drug-rich domains were excluded to the surface of the microspheres, and subsequent release of both drugs from the microspheres was rapid and reflected this surface location.
authors.affiliation: Faculty of Pharmaceutical Science, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada.
authors.forename: Samuel E
authors.initials: SE
authors.lastname: Gilchrist
authors.forename: Deborah L
authors.initials: DL
authors.lastname: Rickard
authors.forename: Kevin
authors.initials: K
authors.lastname: Letchford
authors.forename: David
authors.initials: D
authors.lastname: Needham
authors.forename: Helen M
authors.initials: HM
authors.lastname: Burt
mesh_terms: D002152:Calorimetry, Differential Scanning; D004339:Drug Compounding; D005672:Fusidic Acid / Q000737:chemistry*; D019344:Lactic Acid / Q000737:chemistry*; D018613:Microscopy, Confocal; D008863:Microspheres; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D012293:Rifampin / Q000737:chemistry*; D013059:Spectrum Analysis, Raman
chemical_list: D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D005672:Fusidic Acid; D012293:Rifampin